Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Bladder Cancer, July 2018

Free Subscription


Abstracts

Retrieve all available abstracts of the following 160 articles:
HTML format


 

Single Articles

  1. TANAKA H, Yoshida S, Koga F, Toda K, et al
    Impact of Immunohistochemistry-Based Subtypes in Muscle-Invasive Bladder Cancer on Response to Chemoradiotherapy.
    Int J Radiat Oncol Biol Phys. 2018 Jun 27. pii: S0360-3016(18)31021.
    Abstract    

    Abstract available

  2. APFELTHALER C, Skoll K, Ciola R, Gabor F, et al
    A Doxorubicin loaded colloidal delivery system for the intravesical therapy of non-muscle invasive bladder cancer using wheat germ agglutinin as targeter.
    Eur J Pharm Biopharm. 2018 Jun 27. pii: S0939-6411(18)30082.
    Abstract    

    Abstract available

  3. BEN WAFI S, Kallel A, Ben Fradj MK, Sallemi A, et al
    Haplotype-based association of Vascular Endothelial Growth Factor gene polymorphisms with urothelial bladder cancer risk in Tunisian population.
    J Clin Lab Anal. 2018 Jun 29:e22610. doi: 10.1002/jcla.22610.
    Abstract    

    Abstract available

  4. JOHNSON SB, Yu JB
    Bladder Preserving Trimodality Therapy for Muscle-Invasive Bladder Cancer.
    Curr Oncol Rep. 2018;20:66.
    Abstract    

    Abstract available

  5. RINALDETTI S, Wirtz R, Worst TS, Hartmann A, et al
    FOXM1 predicts disease progression in non-muscle invasive bladder cancer.
    J Cancer Res Clin Oncol. 2018 Jun 29. pii: 10.1007/s00432-018-2694.
    Abstract    

    Abstract available

  6. DUDEK AM, Vermeulen SH, Kolev D, Grotenhuis AJ, et al
    Identification of an enhancer region within the TP63/LEPREL1 locus containing genetic variants associated with bladder cancer risk.
    Cell Oncol (Dordr). 2018 Jun 28. pii: 10.1007/s13402-018-0393.
    Abstract    

    Abstract available

  7. WILLIAMS SB, Shan Y, Jazzar U, Mehta HB, et al
    Comparing Survival Outcomes and Costs Associated With Radical Cystectomy and Trimodal Therapy for Older Adults With Muscle-Invasive Bladder Cancer.
    JAMA Surg. 2018 Jun 27. pii: 2685879. doi: 10.1001/jamasurg.2018.1680.
    Abstract    

    Abstract available

  8. LIN N, Wu YP, Lin YZ, Tao X, et al
    Risk factors for upper tract urothelial recurrence following local excision of bladder cancer.
    Cancer Med. 2018 Jun 28. doi: 10.1002/cam4.1642.
    Abstract    

    Abstract available


  9. Erdafitinib Efficacious in Bladder Cancer.
    Cancer Discov. 2018 Jun 27. pii: 2159-8290.CD-NB2018.
    Abstract    

    Abstract available

  10. WANG J, Fang R, Wang L, Chen G, et al
    Identification of Carbonic Anhydrase IX as a Novel Target for Endoscopic Molecular Imaging of Human Bladder Cancer.
    Cell Physiol Biochem. 2018;47:1565-1577.
    Abstract    

    Abstract available

  11. FLETCHER SA, Harmouch SS, Krimphove MJ, Cole AP, et al
    Characterizing trends in treatment modalities for localized muscle-invasive bladder cancer in the pre-immunotherapy era.
    World J Urol. 2018 Jun 14. pii: 10.1007/s00345-018-2371.
    Abstract    

    Abstract available

  12. RINGUETTE-GOULET C, Bolduc S, Pouliot F
    Modeling human bladder cancer.
    World J Urol. 2018 Jun 14. pii: 10.1007/s00345-018-2369.
    Abstract    

    Abstract available

  13. KRABBE LM, Margulis V, Schrader AJ, Shariat SF, et al
    Molecularly-driven precision medicine for advanced bladder cancer.
    World J Urol. 2018 Jun 8. pii: 10.1007/s00345-018-2354.
    Abstract    

    Abstract available

  14. XIA Y, Yuan M, Li S, Thuan UT, et al
    Apigenin suppresses IL-1beta-induced expression of urokinase-type plasminogen activator receptor by inhibiting MAPK-mediated AP-1 and NF-small ka, CyrillicB signaling in human bladder cancer T24 cells.
    J Agric Food Chem. 2018 Jun 27. doi: 10.1021/acs.jafc.8b02351.
    Abstract    

    Abstract available

  15. GARCIA-PERDOMO HA, Montes-Cardona CE, Guacheta M, Castillo DF, et al
    Muscle-invasive bladder cancer organ-preserving therapy: systematic review and meta-analysis.
    World J Urol. 2018 Jun 25. pii: 10.1007/s00345-018-2384.
    Abstract    

    Abstract available

  16. BJURLIN MA
    Management of Recurrent Non-Muscle Invasive Bladder Cancer.
    Rev Urol. 2018;20:38-40.
    Abstract    



  17. VELAZQUEZ N
    Bladder Cancer Academy 2018 Selected Summaries.
    Rev Urol. 2018;20:31-37.
    Abstract    



  18. LI J, Cheng Y, Liu G, Ji Z, et al
    The association of pretreatment serum albumin with outcomes in bladder cancer: a meta-analysis.
    Onco Targets Ther. 2018;11:3449-3459.
    Abstract    

    Abstract available

  19. BOURN J, Cekanova M
    Cyclooxygenase inhibitors potentiate receptor tyrosine kinase therapies in bladder cancer cells in vitro.
    Drug Des Devel Ther. 2018;12:1727-1742.
    Abstract    

    Abstract available

  20. YANG Z, Zhang R, Ge Y, Qin X, et al
    Somatic FGFR3 Mutations Distinguish a Subgroup of Muscle-Invasive Bladder Cancers with Response to Neoadjuvant Chemotherapy.
    EBioMedicine. 2018 Jun 22. pii: S2352-3964(18)30218.
    Abstract    

    Abstract available

  21. FENG SQ, Zhang XY, Fan HT, Sun QJ, et al
    Up-regulation of LncRNA MEG3 inhibits cell migration and invasion and enhances cisplatin chemosensitivity of bladder cancer cells.
    Neoplasma. 2018 Jun 26. doi: 10.4149/neo_2018_180125.
    Abstract    

    Abstract available

  22. GUO H, Li F, Xu W, Chen J, et al
    Mucoadhesive Cationic Polypeptide Nanogel with Enhanced Penetration for Efficient Intravesical Chemotherapy of Bladder Cancer.
    Adv Sci (Weinh). 2018;5:1800004.
    Abstract    

    Abstract available

  23. ZHOU X, Ji H, Zhang H, Xiong T, et al
    Treatment and outcomes of urethral recurrence after orthotopic neobladder replacement in patients with bladder cancer - practice in a single centre.
    J Int Med Res. 2018 Jan 1:300060518782015. doi: 10.1177/0300060518782015.
    Abstract    

    Abstract available

  24. DAVIDSON MB, Pan D
    Erratum to "An updated meta-analysis of pioglitazone exposure and bladder cancer and comparison to the drug's effect on cardiovascular disease and non-alcoholic steatohepatitis" [Diab. Res. Clin. Pract. 135 (2018) 102-110].
    Diabetes Res Clin Pract. 2018 Jun 20. pii: S0168-8227(18)30968.
    Abstract    



  25. ISLAMOGLU E, Anil H, Erol I, Tas S, et al
    Robotic radical cystectomy for the management of bladder cancer: Analysis of operative and pathological outcomes of eighteen patient.
    Turk J Urol. 2018;44:311-315.
    Abstract    

    Abstract available

  26. MI Y, Zhao Y, Shi F, Zhang M, et al
    Diagnostic accuracy of urine cytokeratin 20 for bladder cancer: A meta-analysis.
    Asia Pac J Clin Oncol. 2018 Jun 22. doi: 10.1111/ajco.13024.
    Abstract    

    Abstract available

  27. SORIA F, Droller MJ, Lotan Y, Gontero P, et al
    An up-to-date catalog of available urinary biomarkers for the surveillance of non-muscle invasive bladder cancer.
    World J Urol. 2018 Jun 21. pii: 10.1007/s00345-018-2380.
    Abstract    

    Abstract available

  28. VOSKUILEN CS, Fransen van de Putte EE, Perez-Reggeti JI, van Werkhoven E, et al
    Prostate sparing cystectomy for bladder cancer: A two-center study.
    Eur J Surg Oncol. 2018 Jun 8. pii: S0748-7983(18)31115.
    Abstract    

    Abstract available

  29. SALTZMAN AF, Cost NG
    Current Treatment of Pediatric Bladder and Prostate Rhabdomyosarcoma.
    Curr Urol Rep. 2018;19:11.
    Abstract    

    Abstract available

  30. HOU T, Zhou L, Wang L, Kazobinka G, et al
    Leupaxin Promotes Bladder Cancer Proliferation, Metastasis, and Angiogenesis Through the PI3K/AKT Pathway.
    Cell Physiol Biochem. 2018;47:2250-2260.
    Abstract    

    Abstract available

  31. LI Z, Li Y, Lu Q, Chen J, et al
    Value of repeat radical transurethral resection for selected patients with muscle-invasive bladder cancer.
    ANZ J Surg. 2018 Jul 5. doi: 10.1111/ans.14709.
    Abstract    

    Abstract available

  32. HAMEED DA, Yassa HA, Agban MN, Hanna RT, et al
    Correction to: Genetic aberrations of the K-ras proto-oncogene in bladder cancer in relation to pesticide exposure.
    Environ Sci Pollut Res Int. 2018 Jul 3. pii: 10.1007/s11356-018-2639.
    Abstract    

    Abstract available

  33. MUKHERJEE N, Svatek R
    Cancer Immune Therapy: Prognostic Significance and Implications for Therapy of PD-1 in BCG-Relapsing Bladder Cancer.
    Ann Surg Oncol. 2018 Jul 3. pii: 10.1245/s10434-018-6610.
    Abstract    



  34. KOJIMA T, Nishiyama H, Ozono S, Hinotsu S, et al
    Clinical evaluation of two consecutive UroVysion fluorescence in situ hybridization tests to detect intravesical recurrence of bladder cancer: a prospective blinded comparative study in Japan.
    Int J Clin Oncol. 2018 Jul 3. pii: 10.1007/s10147-018-1311.
    Abstract    

    Abstract available

  35. OBARA W, Hara I, Kato Y, Kato R, et al
    Immunotherapy with cancer peptides in combination with intravesical bacillus Calmette-Guerin for patients with non-muscle invasive bladder cancer.
    Cancer Immunol Immunother. 2018 Jul 3. pii: 10.1007/s00262-018-2197.
    Abstract    

    Abstract available

  36. YAN H, Xie H, Ying Y, Li J, et al
    Pioglitazone use in patients with diabetes and risk of bladder cancer: a systematic review and meta-analysis.
    Cancer Manag Res. 2018;10:1627-1638.
    Abstract    

    Abstract available

  37. SEVCENCO S, Maj-Hes AB, Hruby S, Ponhold L, et al
    Apparent diffusion coefficient values obtained by unenhanced MRI predicts disease-specific survival in bladder cancer.
    Clin Radiol. 2018 Jun 30. pii: S0009-9260(18)30215.
    Abstract    

    Abstract available

  38. HURLE R, Buffi N, Lista G, Cardone P, et al
    Long-term outcomes of high grade T1 bladder cancer treated with intravesical Bacille Calmette-Guerin therapy: a single-institutional experience.
    Minerva Urol Nefrol. 2018 Jul 3. pii: S0393-2249.18.03042.
    Abstract    

    Abstract available

  39. JAMALI E, Barani S, Yousefinejad F, Ariafar A, et al
    KIRs gene content diversity in Iranians with urothelial bladder cancer.
    Mol Biol Rep. 2018 Jul 2. pii: 10.1007/s11033-018-4221.
    Abstract    

    Abstract available

  40. HANZE J, Kessel F, Di Fazio P, Hofmann R, et al
    Effects of multi and selective targeted tyrosine kinase inhibitors on function and signaling of different bladder cancer cells.
    Biomed Pharmacother. 2018;106:316-325.
    Abstract    

    Abstract available

  41. LIU Y, Ding M, Liao X, Gao Q, et al
    High expression of enhancer RNA MARC1 or its activation by DHT is associated with the malignant behavior in bladder cancer.
    Exp Cell Res. 2018 Jun 28. pii: S0014-4827(18)30373.
    Abstract    

    Abstract available

  42. DONG BW, Zhang WB, Qi SM, Yan CY, et al
    Transactivation of PTGS2 by PAX5 signaling potentiates cisplatin resistance in muscle-invasive bladder cancer cells.
    Biochem Biophys Res Commun. 2018 Jun 28. pii: S0006-291X(18)31470.
    Abstract    

    Abstract available

  43. LEMANSKA-PEREK A, Lis-Kuberka J, Lepczynski A, Dratwa-Chalupnik A, et al
    Potential plasma biomarkers of bladder cancer identified by proteomic analysis: A pilot study.
    Adv Clin Exp Med. 2018 Jul 2. doi: 10.17219/acem/79296.
    Abstract    

    Abstract available

  44. LEE JY, Yun SJ, Jeong P, Piao XM, et al
    Identification of differentially expressed miRNAs and miRNA-targeted genes in bladder cancer.
    Oncotarget. 2018;9:27656-27666.
    Abstract    

    Abstract available

  45. WEI W, Wang M, Li Y, Meng Q, et al
    Muscarinic cholinergic signaling and overactive bladder-like symptoms associated with invasive bladder cancer.
    Oncol Lett. 2018;16:775-784.
    Abstract    

    Abstract available

  46. SHIN SS, Noh DH, Hwang B, Lee JW, et al
    Inhibitory effect of Au@Pt-NSs on proliferation, migration, and invasion of EJ bladder carcinoma cells: involvement of cell cycle regulators, signaling pathways, and transcription factor-mediated MMP-9 expression.
    Int J Nanomedicine. 2018;13:3295-3310.
    Abstract    

    Abstract available

  47. RAMSEY SA
    A Method for Cross-Species Visualization and Analysis of RNA-Sequence Data.
    Methods Mol Biol. 2018;1702:291-305.
    Abstract    

    Abstract available

  48. ARYA SK, Estrela P
    Electrochemical ELISA-based platform for bladder cancer protein biomarker detection in urine.
    Biosens Bioelectron. 2018;117:620-627.
    Abstract    

    Abstract available

  49. TANG Z
    Effects of human enhancer of filamentation 1 (HEF1) gene on the proliferation, invasion and metastasis of bladder cancer cells.
    J BUON. 2018;23:782-786.
    Abstract    

    Abstract available

  50. ZHONG X, Long Z, Wu S, Xiao M, et al
    LncRNA-SNHG7 regulates proliferation, apoptosis and invasion of bladder cancer cells assurance guidelines.
    J BUON. 2018;23:776-781.
    Abstract    

    Abstract available

  51. DE JONG JJ, Stoop H, Nieboer D, Boormans JL, et al
    Concordance of PD-L1 expression in matched urothelial bladder cancer specimens.
    Histopathology. 2018 Jul 12. doi: 10.1111/his.13710.
    Abstract    

    Abstract available

  52. SOUBRA A, Gencturk M, Froelich J, Balaji P, et al
    FDG-PET/CT for Assessing the Response to Neoadjuvant Chemotherapy in Bladder Cancer Patients.
    Clin Genitourin Cancer. 2018 May 31. pii: S1558-7673(18)30344.
    Abstract    

    Abstract available

  53. LIU X, Liu X, Wu Y, Fang Z, et al
    MicroRNA-34a Attenuates Metastasis and Chemoresistance of Bladder Cancer Cells by Targeting the TCF1/LEF1 Axis.
    Cell Physiol Biochem. 2018;48:87-98.
    Abstract    

    Abstract available

  54. KARAVANA SY, Senyigit ZA, Caliskan C, Sevin G, et al
    Gemcitabine hydrochloride microspheres used for intravesical treatment of superficial bladder cancer: a comprehensive in vitro/ex vivo/in vivo evaluation.
    Drug Des Devel Ther. 2018;12:1959-1975.
    Abstract    

    Abstract available

  55. YOSHIMURA H, Okano T, Inui K, Nakamura H, et al
    Ultrasonographic findings in a patient with reactive arthritis induced by intravesical BCG therapy for bladder cancer.
    J Med Ultrason (2001). 2018 Jul 10. pii: 10.1007/s10396-018-0889.
    Abstract    

    Abstract available

  56. FERRO M, Vartolomei MD, Russo GI, Cantiello F, et al
    An increased body mass index is associated with a worse prognosis in patients administered BCG immunotherapy for T1 bladder cancer.
    World J Urol. 2018 Jul 10. pii: 10.1007/s00345-018-2397.
    Abstract    

    Abstract available

  57. PETTENATI C, Ingersoll MA
    Mechanisms of BCG immunotherapy and its outlook for bladder cancer.
    Nat Rev Urol. 2018 Jul 10. pii: 10.1038/s41585-018-0055.
    Abstract    

    Abstract available

  58. MCALPINE K, Fergusson DA, Breau RH, Reynolds LF, et al
    Radiotherapy with radical cystectomy for bladder cancer: A systematic review and meta-analysis.
    Can Urol Assoc J. 2018 May 28. pii: cuaj.5244. doi: 10.5489/cuaj.5244.
    Abstract    

    Abstract available

  59. DO J, Lee SW, Jeh SU, Hwa JS, et al
    Overnight continuous saline irrigation after transurethral resection for non-muscle-invasive bladder cancer is helpful in prevention of early recurrence.
    Can Urol Assoc J. 2018 Jun 8. pii: cuaj.5122. doi: 10.5489/cuaj.5122.
    Abstract    

    Abstract available

  60. ZHANG D, Wang Z, Wang L, Wang Z, et al
    High-Performance Identification of Human Bladder Cancer Using Signal Self-Amplifiable Photoacoustic Nanoprobe.
    ACS Appl Mater Interfaces. 2018 Jul 10. doi: 10.1021/acsami.8b08357.
    Abstract    

    Abstract available

  61. ANNELS NE, Arif M, Simpson GR, Denyer M, et al
    Oncolytic Immunotherapy for Bladder Cancer Using Coxsackie A21 Virus.
    Mol Ther Oncolytics. 2018;9:1-12.
    Abstract    

    Abstract available

  62. YILMAZ Y, Kahya MC, Dilek FH, Kose O, et al
    Can tumor recurrence be reduced with plasma-kinetic vaporization of the area around the tumor in nonmuscle invasive bladder cancer?
    Investig Clin Urol. 2018;59:223-231.
    Abstract    

    Abstract available

  63. FALKE J, Parkkinen J, Vaahtera L, Hulsbergen-van de Kaa CA, et al
    Curcumin as Treatment for Bladder Cancer: A Preclinical Study of Cyclodextrin-Curcumin Complex and BCG as Intravesical Treatment in an Orthotopic Bladder Cancer Rat Model.
    Biomed Res Int. 2018;2018:9634902.
    Abstract    

    Abstract available

  64. PANDEY S, Bourn J, Cekanova M
    Mutations of p53 decrease sensitivity to the anthracycline treatments in bladder cancer cells.
    Oncotarget. 2018;9:28514-28531.
    Abstract    

    Abstract available

  65. HU B, Yan Y, Tong F, Xu L, et al
    Lumbrokinase/paclitaxel nanoparticle complex: potential therapeutic applications in bladder cancer.
    Int J Nanomedicine. 2018;13:3625-3640.
    Abstract    

    Abstract available

  66. ZHANG M, Du H, Huang Z, Zhang P, et al
    Thymoquinone induces apoptosis in bladder cancer cell via endoplasmic reticulum stress-dependent mitochondrial pathway.
    Chem Biol Interact. 2018 Jul 2. pii: S0009-2797(18)30167.
    Abstract    

    Abstract available

  67. PAREKH DJ, Reis IM, Castle EP, Gonzalgo ML, et al
    Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial.
    Lancet. 2018;391:2525-2536.
    Abstract    

    Abstract available


  68. 9 - Tossicita Da Trattamento Radioterapico E Da Terapia Sistemica Per Neoplasia Vescicale.
    Tumori. 2018;104.
    Abstract    




  69. 8 - Pianificazione E Somministrazione Del Trattamento Radioterapico.
    Tumori. 2018;104.
    Abstract    




  70. 7 - Terapia Nella Malattia In Progressione E Metastatica.
    Tumori. 2018;104.
    Abstract    




  71. 2 - Epidemiologia E Classificazione Istopatologica.
    Tumori. 2018;104.
    Abstract    




  72. 11 - Follow-Up.
    Tumori. 2018;104.
    Abstract    




  73. Linee Guida AIRO-AIRB 2018: Neoplasie della Vescica.
    Tumori. 2018;104.
    Abstract    




  74. 10 - Nuove Tecnologie in Radioterapia E Prospettive Future.
    Tumori. 2018;104.
    Abstract    




  75. 6 - Terapia Trimodale Nel Trattamento Conservativo Della Neoplasia Vescicale.
    Tumori. 2018;104.
    Abstract    




  76. 5 - Trattamento Chirurgico Della Malattia Muscolo-Invasiva E Localmente Avanzata (MIBC).
    Tumori. 2018;104.
    Abstract    




  77. 4 - Trattamento Chirurgico Della Malattia Non Muscolo-Invasiva (NMIBC).
    Tumori. 2018;104.
    Abstract    




  78. 3 - Diagnosi E Stadiazione.
    Tumori. 2018;104.
    Abstract    



  79. LIU ZH, Shi JY, Wang HY, Ye HY, et al
    [CT texture analysis in bladder carcinoma: histologic grade characterization].
    Zhonghua Zhong Liu Za Zhi. 2018;40:379-383.
    Abstract    

    Abstract available

  80. NAZZANI S, Preisser F, Mazzone E, Tian Z, et al
    In-hospital length of stay after major surgical oncological procedures.
    Eur J Surg Oncol. 2018;44:969-974.
    Abstract    

    Abstract available

  81. KANO H, Miwa S, Koshida K, Kawai K, et al
    Successful Treatment of a Large Superficial Bladder Cancer with Neoadjuvant Arterial Infusion Chemotherapy: A Case Report.
    Case Rep Oncol. 2018;11:383-387.
    Abstract    

    Abstract available

  82. ZHANG XG, Zhang T, Li CY, Zhang MH, et al
    CD164 promotes tumor progression and predicts the poor prognosis of bladder cancer.
    Cancer Med. 2018 Jul 18. doi: 10.1002/cam4.1607.
    Abstract    

    Abstract available

  83. HAUTMANN R, Bolenz C
    Declining Use of Orthotopic Reconstruction for Bladder Cancer.
    Ann Surg Oncol. 2018 Jul 18. pii: 10.1245/s10434-018-6570.
    Abstract    



  84. FAN TW, Malhi H, Varghese B, Cen S, et al
    Computed tomography-based texture analysis of bladder cancer: differentiating urothelial carcinoma from micropapillary carcinoma.
    Abdom Radiol (NY). 2018 Jul 18. pii: 10.1007/s00261-018-1694.
    Abstract    

    Abstract available

  85. SWALARZ M, Swalarz G, Juszczak K, Maciukiewicz P, et al
    Correlation between malnutrition, body mass index and complications in patients with urinary bladder cancer who underwent radical cystectomy.
    Adv Clin Exp Med. 2018 Jul 18. doi: 10.17219/acem/89863.
    Abstract    

    Abstract available

  86. KRAFFT U, Reis H, Ingenwerth M, Kovalszky I, et al
    Nuclear Localization of Robo is Associated with Better Survival in Bladder Cancer.
    Pathol Oncol Res. 2018 Jul 17. pii: 10.1007/s12253-018-0447.
    Abstract    

    Abstract available

  87. SAHEB SHARIF-ASKARI N, Bendardaf R, Saheb Sharif-Askari F, El Tabbal AM, et al
    Incidence of bladder cancer in Benghazi, Libya over the past three decades.
    Sci Rep. 2018;8:10822.
    Abstract    

    Abstract available

  88. STEINBERG RL, Thomas LJ, O'Donnell MA
    Combination Intravesical Chemotherapy for Non-muscle-invasive Bladder Cancer.
    Eur Urol Focus. 2018 Jul 13. pii: S2405-4569(18)30171.
    Abstract    

    Abstract available

  89. HIGASHIYAMA A, Komori T, Juri H, Inada Y, et al
    Detectability of residual invasive bladder cancer in delayed (18)F-FDG PET imaging with oral hydration using 500 mL of water and voiding-refilling.
    Ann Nucl Med. 2018 Jul 16. pii: 10.1007/s12149-018-1280.
    Abstract    

    Abstract available

  90. TREE AC, Jones K, Hafeez S, Sharabiani MTA, et al
    Dose-limiting Urinary Toxicity With Pembrolizumab Combined With Weekly Hypofractionated Radiation Therapy in Bladder Cancer.
    Int J Radiat Oncol Biol Phys. 2018;101:1168-1171.
    Abstract    

    Abstract available

  91. CHEN M, Wu R, Li G, Liu C, et al
    Motor neuron and pancreas homeobox 1/HLXB9 promotes sustained proliferation in bladder cancer by upregulating CCNE1/2.
    J Exp Clin Cancer Res. 2018;37:154.
    Abstract    

    Abstract available

  92. HARTANA CA, Ahlen Bergman E, Broome A, Berglund S, et al
    Tissue-resident memory T cells are epigenetically cytotoxic with signs of exhaustion in human urinary bladder cancer.
    Clin Exp Immunol. 2018 Jul 15. doi: 10.1111/cei.13183.
    Abstract    

    Abstract available

  93. CHU J, Li N, Li F
    A risk score staging system based on the expression of seven genes predicts the outcome of bladder cancer.
    Oncol Lett. 2018;16:2091-2096.
    Abstract    

    Abstract available

  94. GUO P, Shang W, Peng L, Wang L, et al
    A gel system for single instillation of non-muscle-invasive bladder Cancer: A "divide-and-rule" strategy.
    J Control Release. 2018;285:46-55.
    Abstract    

    Abstract available

  95. PENG D, Ge G, Gong Y, Zhan Y, et al
    Vitamin C increases 5-hydroxymethylcytosine level and inhibits the growth of bladder cancer.
    Clin Epigenetics. 2018;10:94.
    Abstract    

    Abstract available

  96. HOSNY K, Luk A
    Urinary schistosomiasis presented as bladder malignancy with pulmonary metastases: a case report.
    Ann R Coll Surg Engl. 2018;100:e145-e146.
    Abstract    

    Abstract available

  97. SOUSA ESCANDON A, Leon Mata J, Sousa Gonzalez D, Alvarez Casal M, et al
    Neoadjuvant chemohyperthermia: Our experience after 10 years.
    Arch Esp Urol. 2018;71:438-446.
    Abstract    

    Abstract available

  98. GUERRERO-RAMOS F, Castellano-Gauna D, Garcia-Rojo E, Duarte-Ojeda JM, et al
    [Mitomycin C HIVEC. Update and results in high risk patients.]
    Arch Esp Urol. 2018;71:417-425.
    Abstract    

    Abstract available

  99. SOLSONA E
    [EMDA with MMC. Critical review.]
    Arch Esp Urol. 2018;71:409-416.
    Abstract    

    Abstract available

  100. BARCLAY J, Creswell J, Leon J
    Cancer immunotherapy and the PD-1/PD-L1 checkpoint pathway.
    Arch Esp Urol. 2018;71:393-399.
    Abstract    

    Abstract available

  101. RIOS GONZALEZ E, Martinez-Pineiro L
    [New endovesical chemotherapy drugs and application vehicles.]
    Arch Esp Urol. 2018;71:384-392.
    Abstract    

    Abstract available

  102. DOMINGUEZ-ESCRIG JL
    [Immediate post TURBT MMC instillation.]
    Arch Esp Urol. 2018;71:376-383.
    Abstract    

    Abstract available

  103. CARBALLIDO JA, Rodriguez Monsalve M
    [Mechanism of action of intravesical BCG. Biological bases and clinical applicability.]
    Arch Esp Urol. 2018;71:358-375.
    Abstract    

    Abstract available

  104. SANCHEZ VAZQUEZ A, Pereira Arias JG, Gamarra Quintanilla M, Urdaneta Salegui F, et al
    [BCG therapy in NMIBC: How much and for how long?.]
    Arch Esp Urol. 2018;71:349-357.
    Abstract    

    Abstract available

  105. ASHTON A, Murthy Kusuma VR, Crew J, Mostafid AH, et al
    BCG therapy in NMIBC: How much and for how long?.
    Arch Esp Urol. 2018;71:342-348.
    Abstract    

    Abstract available

  106. UNDA-URZAIZ M
    [Future advances in the endovesical treatment of NMIBC.]
    Arch Esp Urol. 2018;71:328-331.
    Abstract    



  107. MOEEN AM, Safwat AS, Gadelmoula MM, Moeen SM, et al
    Does the site of the orthotopic neobladder outlet matter? A prospective randomized comparative study.
    Eur J Surg Oncol. 2018;44:847-852.
    Abstract    

    Abstract available

  108. HUSSMANN D, Hansen LL
    Methylation-Sensitive High Resolution Melting (MS-HRM).
    Methods Mol Biol. 2018;1708:551-571.
    Abstract    

    Abstract available

  109. GARJE R, Chau JJ, Chung J, Wanat K, et al
    Acute Flare of Bullous Pemphigus With Pembrolizumab Used for Treatment of Metastatic Urothelial Cancer.
    J Immunother. 2018;41:42-44.
    Abstract    

    Abstract available

  110. BUS SJEA, Leus NG, Oosterveld BJ, Van Gellekom MPR, et al
    An evaluation of our experience in position verification of catheters used for interstitial high-dose-rate brachytherapy of solitary bladder tumors.
    Brachytherapy. 2018;17:24-30.
    Abstract    

    Abstract available

  111. HU J, Chen JB, Cui Y, Zhu YW, et al
    Association of metformin intake with bladder cancer risk and oncologic outcomes in type 2 diabetes mellitus patients: A systematic review and meta-analysis.
    Medicine (Baltimore). 2018;97:e11596.
    Abstract    

    Abstract available

  112. POCH MA, Patel S, Garcia-Getting R
    The present and future enhanced recovery after surgery for bladder cancer.
    Int Braz J Urol. 2018;44.
    Abstract    



  113. HADAMI K, Dakka N, Bensaid M, El Ahanidi H, et al
    Evaluation of glutathione S-transferase pi 1 expression and gene promoter methylation in Moroccan patients with urothelial bladder cancer.
    Mol Genet Genomic Med. 2018 Jul 24. doi: 10.1002.
    Abstract    

    Abstract available

  114. CARTA A, Pavanello S, Mastrangelo G, Fedeli U, et al
    Impact of Occupational Exposures and Genetic Polymorphisms on Recurrence and Progression of Non-Muscle-Invasive Bladder Cancer.
    Int J Environ Res Public Health. 2018;15.
    Abstract    

    Abstract available

  115. LI J, Li Y, Meng F, Fu L, et al
    Knockdown of long non-coding RNA LINC00511 suppresses proliferation and promotes apoptosis of bladder cancer cells via suppressing Wnt/beta-catenin signaling pathway.
    Biosci Rep. 2018 Jul 24. pii: BSR20171701. doi: 10.1042/BSR20171701.
    Abstract    

    Abstract available

  116. GIULIANELLI R, Gentile BC, Mirabile G, Albanesi L, et al
    Narrow Band Imaging reduces persistence of cancer in patients with pT1 high grade bladder cancer.
    Eur J Surg Oncol. 2018 Jun 18. pii: S0748-7983(18)31125.
    Abstract    

    Abstract available

  117. RAMAKRISHNAN S, Huss W, Foster B, Ohm J, et al
    Transcriptional changes associated with in vivo growth of muscle-invasive bladder cancer cell lines in nude mice.
    Am J Clin Exp Urol. 2018;6:138-148.
    Abstract    

    Abstract available

  118. KUTWIN P, Konecki T, Borkowska EM, Traczyk-Borszynska M, et al
    Urine miRNA as a potential biomarker for bladder cancer detection - a meta-analysis.
    Cent European J Urol. 2018;71:177-185.
    Abstract    

    Abstract available

  119. FANTINI D, Meeks JJ
    The BBN model: a mouse bladder cancer model featuring basal-subtype gene expression and MLL3/MLL4 genetic disruption.
    Oncoscience. 2018;5.
    Abstract    



  120. VAN VALENBERG FJP, Strauss-Ayali D, Agmon-Gerstein Y, Friedman A, et al
    Assessment of the efficacy of repeated instillations of mitomycin C mixed with a thermosensitive hydrogel in an orthotopic rat bladder cancer model.
    Ther Adv Urol. 2018;10:213-221.
    Abstract    

    Abstract available

  121. SHIN SS, Ko MC, Park YJ, Hwang B, et al
    Hydrangenol inhibits the proliferation, migration, and invasion of EJ bladder cancer cells via p21(WAF1)-mediated G1-phase cell cycle arrest, p38 MAPK activation, and reduction in Sp-1-induced MMP-9 expression.
    EXCLI J. 2018;17:531-543.
    Abstract    

    Abstract available

  122. RABY SEM, Choudhury A
    Radiotherapy for High-grade T1 Bladder Cancer.
    Eur Urol Focus. 2018 Jul 19. pii: S2405-4569(18)30183.
    Abstract    

    Abstract available

  123. LIEM EIML, Freund JE, Savci-Heijink CD, de la Rosette JJMCH, et al
    Validation of Confocal Laser Endomicroscopy Features of Bladder Cancer: The Next Step Towards Real-time Histologic Grading.
    Eur Urol Focus. 2018 Jul 19. pii: S2405-4569(18)30178.
    Abstract    

    Abstract available

  124. NI F, Yan CY, Zhou S, Hui PY, et al
    Repression of GRIM19 expression potentiates cisplatin chemoresistance in advanced bladder cancer cells via disrupting ubiquitination-mediated Bcl-xL degradation.
    Cancer Chemother Pharmacol. 2018 Jul 21. pii: 10.1007/s00280-018-3651.
    Abstract    

    Abstract available

  125. MIERNIK A
    [Nonmuscle invasive bladder cancer : Efficacy of electromotive drug administration].
    Urologe A. 2018 Jul 20. pii: 10.1007/s00120-018-0737.
    Abstract    



  126. LAKKIS NA, Adib SM, Hamadeh GN, El-Jarrah RT, et al
    Bladder Cancer in Lebanon: Incidence and Comparison to Regional and Western Countries.
    Cancer Control. 2018;25:1073274818789359.
    Abstract    

    Abstract available

  127. ZHANG G, Zhang Y, Dong D, Wang F, et al
    MCT1 regulates aggressive and metabolic phenotypes in bladder cancer.
    J Cancer. 2018;9:2492-2501.
    Abstract    

    Abstract available

  128. LI M, Liu Y, Zhang X, Liu J, et al
    Transcriptomic analysis of high-throughput sequencing about circRNA, lncRNA and mRNA in bladder cancer.
    Gene. 2018 Jul 16. pii: S0378-1119(18)30815-1. doi: 10.1016/j.gene.2018.
    Abstract    

    Abstract available

  129. THOMAS DE, Kaimakliotis HZ, Rice KR, Pereira JA, et al
    Commentary on "Prognostic effect of carcinoma in situ in muscle-invasive urothelial carcinoma patients receiving neoadjuvant chemotherapy."
    Urol Oncol. 2018;36:345.
    Abstract    

    Abstract available

  130. SOAVE A, Riethdorf S, Dahlem R, Minner S, et al
    Commentary on "Detection and oncological effect of circulating tumor cells in patients with variant urothelial carcinoma histology treated with radical cystectomy."
    Urol Oncol. 2018;36:347-348.
    Abstract    

    Abstract available

  131. DASON S, Goh AC
    Updates on Robotic Intracorporeal Urinary Diversions.
    Curr Urol Rep. 2018;19:28.
    Abstract    

    Abstract available

  132. YI Y, Wu A, Cameron AP
    Nephrogenic adenoma of the bladder: a single institution experience assessing clinical factors.
    Int Braz J Urol. 2018;44:506-511.
    Abstract    

    Abstract available

  133. KIM SY, Kwon WA, Shin SP, Seo HK, et al
    Electrostatic interaction of tumor-targeting adenoviruses with aminoclay acquires enhanced infectivity to tumor cells inside the bladder and has better cytotoxic activity.
    Drug Deliv. 2018;25:49-58.
    Abstract    

    Abstract available

  134. RICHARDSON DB, Cardis E, Daniels RD, Gillies M, et al
    Site-specific Solid Cancer Mortality After Exposure to Ionizing Radiation: A Cohort Study of Workers (INWORKS).
    Epidemiology. 2018;29:31-40.
    Abstract    

    Abstract available

  135. NECCHI A, Lo Vullo S, Raggi D, Perrone F, et al
    Neoadjuvant sorafenib, gemcitabine, and cisplatin administration preceding cystectomy in patients with muscle-invasive urothelial bladder carcinoma: An open-label, single-arm, single-center, phase 2 study.
    Urol Oncol. 2018;36:8.
    Abstract    

    Abstract available

  136. SMITH A, Daneshmand S, Patel S, Pohar K, et al
    Patient-reported Outcomes of Blue Light Flexible Cystoscopy with Hexaminolevulinate (HAL) in the Surveillance of Bladder Cancer: Results from a Prospective Multi-center Study.
    BJU Int. 2018 Jul 6. doi: 10.1111/bju.14481.
    Abstract    

    Abstract available

  137. SMITTENAAR P, Walker AK, McGill S, Kartsonaki C, et al
    Harnessing citizen science through mobile phone technology to screen for immunohistochemical biomarkers in bladder cancer.
    Br J Cancer. 2018 Jul 11. pii: 10.1038/s41416-018-0156.
    Abstract    

    Abstract available

  138. LELO A, Prip F, Harris BT, Solomon D, et al
    STAG2 Is a Biomarker for Prediction of Recurrence and Progression in Papillary Non-Muscle-Invasive Bladder Cancer.
    Clin Cancer Res. 2018 Jun 28. pii: 1078-0432.CCR-17-3244.
    Abstract    

    Abstract available

  139. LI Q, Damish A, Frazier ZJ, Liu D, et al
    ERCC2 Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder Cancer.
    Clin Cancer Res. 2018 Jul 6. pii: 1078-0432.CCR-18-1001.
    Abstract    

    Abstract available

  140. BIELLI P, Panzeri V, Lattanzio R, Mutascio S, et al
    The splicing factor PTBP1 promotes expression of oncogenic splice variants and predicts poor prognosis in patients with non-muscle invasive bladder cancer.
    Clin Cancer Res. 2018 Jul 16. pii: 1078-0432.CCR-17-3850.
    Abstract    

    Abstract available

  141. THOENY HC, Bellin MF, Comperat EM, Thalmann GN, et al
    Vesical Imaging-Reporting and Data System (VI-RADS): Added Value for Management of Bladder Cancer Patients?
    Eur Urol. 2018 Jun 27. pii: S0302-2838(18)30442.
    Abstract    



  142. ECKSTEIN M, Sikic D, Strissel PL, Erlmeier F, et al
    Evolution of PD-1 and PD-L1 Gene and Protein Expression in Primary Tumors and Corresponding Liver Metastases of Metastatic Bladder Cancer.
    Eur Urol. 2018 Jul 11. pii: S0302-2838(18)30456.
    Abstract    



  143. HOVELSON DH, Udager AM, McDaniel AS, Grivas P, et al
    Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications.
    Eur Urol. 2018 Jul 19. pii: S0302-2838(18)30475.
    Abstract    

    Abstract available

  144. PANEBIANCO V, Barentsz J, Narumi Y, Catto J, et al
    Reply to Andrea Necchi, Antonella Messina, and Alberto Briganti's Letter to the Editor re: Valeria Panebianco, Yoshifumi Narumi, Ersan Altun, et al. Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging
    Eur Urol. 2018 Jul 17. pii: S0302-2838(18)30457.
    Abstract    



  145. KRANTZ D, Hartana CA, Winerdal ME, Johansson M, et al
    Neoadjuvant Chemotherapy Reinforces Antitumour T cell Response in Urothelial Urinary Bladder Cancer.
    Eur Urol. 2018 Jul 16. pii: S0302-2838(18)30476.
    Abstract    

    Abstract available

  146. LIN C, Travis RC, Appleby PN, Tipper S, et al
    Pre-diagnostic circulating insulin-like growth factor-I and bladder cancer risk in the European Prospective Investigation into Cancer and Nutrition.
    Int J Cancer. 2018 Jul 4. doi: 10.1002/ijc.31650.
    Abstract    

    Abstract available

  147. KOUTROS S, Baris D, Waddell R, Freeman LEB, et al
    Potential effect modifiers of the arsenic-bladder cancer risk relationship.
    Int J Cancer. 2018 Jul 7. doi: 10.1002/ijc.31720.
    Abstract    

    Abstract available

  148. WANG W, Yang C, Nie H, Qiu X, et al
    LIMK2 acts as an oncogene in bladder cancer and its functional SNP in the microRNA-135a binding site affects bladder cancer risk.
    Int J Cancer. 2018 Jul 14. doi: 10.1002/ijc.31757.
    Abstract    

    Abstract available

  149. NAKAI Y, Inoue K, Tsuzuki T, Shimamoto T, et al
    Oral 5-aminolevulinic acid-mediated photodynamic diagnosis using fluorescence cystoscopy for non-muscle-invasive bladder cancer: A multicenter phase III study.
    Int J Urol. 2018 Jul 12. doi: 10.1111/iju.13718.
    Abstract    

    Abstract available

  150. ZHANG D, Zhou C, Li Y, Gao L, et al
    Amyloid precursor protein is overexpressed in bladder cancer and contributes to the malignant bladder cancer cell behaviors.
    Int J Urol. 2018 Jul 18. doi: 10.1111/iju.13726.
    Abstract    

    Abstract available

  151. OHTAKA M, Kawahara T, Ishiguro Y, Sharma M, et al
    Expression of receptor activator of nuclear factor kappa B ligand in bladder cancer.
    Int J Urol. 2018 Jul 24. doi: 10.1111/iju.13756.
    Abstract    



  152. PENG M, Wang J, Zhang D, Jin H, et al
    PHLPP2 stabilization by p27 mediates its inhibition of bladder cancer invasion by promoting autophagic degradation of MMP2 protein.
    Oncogene. 2018 Jun 21. pii: 10.1038/s41388-018-0374.
    Abstract    

    Abstract available

  153. LEE E, Collazo-Lorduy A, Castillo-Martin M, Gong Y, et al
    Identification of microR-106b as a prognostic biomarker of p53-like bladder cancers by ActMiR.
    Oncogene. 2018 Jul 3. pii: 10.1038/s41388-018-0367.
    Abstract    

    Abstract available

  154. ZHANG T, Yang F, Li W, Liu B, et al
    Suppression of the SDF1/CXCR4/betacatenin axis contributes to bladder cancer cell growth inhibition in vitro and in vivo.
    Oncol Rep. 2018 Jul 4. doi: 10.3892/or.2018.6546.
    Abstract    

    Abstract available

  155. ZHANG H, Qi D, Li J, Peng T, et al
    A novel regulatory circuit of miR152 and DNMT1 in human bladder cancer.
    Oncol Rep. 2018 Jul 10. doi: 10.3892/or.2018.6553.
    Abstract    

    Abstract available

  156. MICHEL C, Vordos D, Dumont C, Basset V, et al
    [Impact of neoadjuvant chemotherapy on the peri-operative morbidity of radical cystectomy for muscle invasive bladder cancer].
    Prog Urol. 2018 Jul 8. pii: S1166-7087(18)30169.
    Abstract    

    Abstract available

  157. BECKFORD VERA DR, Smith CC, Bixby LM, Glatt DM, et al
    Immuno-PET imaging of tumor-infiltrating lymphocytes using zirconium-89 radiolabeled anti-CD3 antibody in immune-competent mice bearing syngeneic tumors.
    PLoS One. 2018;13:e0193832.
    Abstract    

    Abstract available

  158. HARTANA CA, Ahlen Bergman E, Zirakzadeh AA, Krantz D, et al
    Urothelial bladder cancer may suppress perforin expression in CD8+ T cells by an ICAM-1/TGFbeta2 mediated pathway.
    PLoS One. 2018;13:e0200079.
    Abstract    

    Abstract available

  159. FERDOSI S, Ho TH, Castle EP, Stanton ML, et al
    Behavior of blood plasma glycan features in bladder cancer.
    PLoS One. 2018;13:e0201208.
    Abstract    

    Abstract available

  160. BANSAL A, Yang F, Xi T, Zhang Y, et al
    In vivo wireless photonic photodynamic therapy.
    Proc Natl Acad Sci U S A. 2018;115:1469-1474.
    Abstract    

    Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design:


;